Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab

Objective: The goal is to evaluate avelumab, an anti-PD-L1 monoclonal immunoglobulin G antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse xenografts for clinical translation. Methods: [ 89 Zr]Zr-DFO-PD-L1 monoclonal antibody (mAb) was synthesized using avelumab conju...

Full description

Bibliographic Details
Main Authors: Elaine M. Jagoda PhD, Olga Vasalatiy PhD, Falguni Basuli PhD, Ana Christina L. Opina PhD, Mark R. Williams BS, Karen Wong MS, Kelly C. Lane BS, Steve Adler PhD, Anita Thein Ton MS, Lawrence P. Szajek PhD, Biying Xu PhD, Donna Butcher BS, Elijah F. Edmondson DVM, PhD, Rolf E. Swenson PhD, John Greiner PhD, James Gulley MD, PhD, Janet Eary MD, Peter L. Choyke MD
Format: Article
Language:English
Published: SAGE Publications 2019-04-01
Series:Molecular Imaging
Online Access:https://doi.org/10.1177/1536012119829986

Internet

https://doi.org/10.1177/1536012119829986

Similar Items